Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Sep - Newspaper Publication regarding re-lodgement of transfer deed.
Source: Bse
Brooks Laboratories Limited (BROOKS)
Small CapPharma stocks · Small cap · NSE
Brooks Laboratories Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 01:58 pm ISTDetails
Quote21 Oct, 01:58 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result13 Aug, 07:54 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
72BullishSMA20 -3.5% / mo · MACD + · sector +4.4pp vs Nifty 500 (3M)
Stock trend: 53
Sector RS: 100
Sector 3M: -1.7% vs Nifty 500 -6.1%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
BROOKSD candles · FIT view+1.5%TODAY · PROVISIONALLatest price ₹62.69 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-3.7%
RSI
49
MACD hist
0.46
52W pos
30%
2026-10-21O ₹65.07H ₹65.27L ₹61.05C ₹62.69Vol 58,312 shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
BROOKSNifty PharmaNifty 500
- BROOKS
- -4.0%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +1.6 pp
Chart stats
19 Oct 2026- From 52W high
- -50.5%
- 52W range position
- 30%
- ATR (14)
- 7.6%
- Volume vs 20D
- 0.23x
- Avg traded value
- ₹1.4 Cr
- 20D price channel
- ₹53 - ₹75.6
₹131.6
₹36.3 - ₹131.6
₹5
Latest completed session
20-session average
85.3% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · UNDERVALUED61
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -10.0% · PAT -118.7% YoY
Technical
Bullish72
Price trend and sector-relative-strength timing.
Valuation
Legacy model+69.0%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence68
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100Rev -10% YoY · PAT -119% YoY · margin compression · +14% QoQ
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹23 Cr | -10.0% | +13.6% |
| EBITDA | ₹-1.3 Cr | -142.8% | -297.1% |
| Operating margin | -5.8% | -1811 bps | -920 bps |
| PAT | ₹-1.8 Cr | -118.7% | -217.8% |
| PAT margin | -7.8% | -4535 bps | -1532 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 12.10
- P/B
- 1.30
- EV/EBITDA
- 33.80
- Market Cap
- 160.00Cr
Profitability
- ROE
- 22.00%
- ROCE
- 21.20%
- ROA
- 8.78%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 2.00%
- EPS 5Y
- 27.00%
- Revenue 3Y
- 11.00%
- EPS 3Y
- 47.00%
Balance Sheet
- Debt/Equity
- 0.07
- Interest Coverage
- 3.00×
- Altman Z
- 5.50
- Book Value
- 41.60
Cash Flow
- FCF Yield
- 3.75%
- FCF Positive Y
- 1/5
- OCF
- 9.00 Cr
- EPS TTM
- 4.49
Shareholding
- Promoter Hold
- 52.62%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 19%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 23.0+13.6% vs prev
Net Profit
₹ CrLatest: -1.8-217.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 49.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~3.2% over last month) — short-term momentum negative.
- RSI(14) at 49 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 49% off 52W high · 73% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
33
RS percentile
Stage 3 Topping
1M return
+5.8%
3M return
-4.0%
6M return
+6.2%
1Y return
-39.1%
RS 1D
+3
RS 20D
+14
Sector rank
#1
Industry rank
#11
Stage evidence
- 41.9% below the 52-week closing high after prior strength.
- The 30-week proxy has stalled (-0.2% over 20 sessions).
- Price has not yet confirmed a full Stage 4 downtrend.
50-DMA
price above
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 49.67-2.70%
RS vs Nifty 50050
Valuation & peers
U-Score 61 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 61 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · UNDERVALUEDValuation19/30
Growth17/25
Quality14/20
Balance Sheet10/15
Cash Flow3/10
Piotroski
7/9 (+5)
Penalties
-7
Raw sum
61
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
61/100 · legacy band UNDERVALUED
Positive drivers
- FCF yield is supportive at 3.8%.
- Piotroski is strong at 7/9.
- Fair-value margin of safety is positive at 69.0%.
Main drags
- Penalty bucket subtracts 7 points.
- Cash flow is weaker at 3/10; verify the latest quarterly trend.
- Valuation is weaker at 19/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
12.1
PB
1.3
EV/EBITDA
33.8
ROE
22.0%
ROCE
21.2%
FCF Yield
3.8%
Debt/Equity
0.1
MoS
+69.0%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
61
Previous: 60 (+1)
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+69.0%
Previous: +67.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
60
60
60
60
60
60
60
60
60
60
60
60
Factor attribution
Valuation
19+1
was 18
Modelled fair value
Graham Number
₹64.83
+3.3% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹202.05
+69.0% MoS
PEG
0.35
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
BALPHARMA
Small
Bal Pharma Limited
Pharmaceuticals
match 164
23
23.6
7.9%
-44%
OVERVALUED
ALPA
Small
Alpa Laboratories Limited
Pharmaceuticals
match 163
32
30.6
8.4%
+40%
WATCHLIST
BALAXI
Small
BALAXI PHARMACEUTICALS LIMITED
Pharmaceuticals
match 162
9
51.7
0.6%
-5589%
OVERVALUED
QUESTLAB
SME
Quest Laboratories Ltd.
Pharmaceuticals
match 161
70
11.3
16.6%
+78%
UNDERVALUED
JHS
Small
JHS Svendgaard Laboratories Limited
Pharmaceuticals
match 160
12
—
-1.2%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Brooks Laboratories Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
68Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 56th percentile of the scored universe and 43rd percentile within Pharma. Main check: results consistency is weak at 26/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
5 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
56th percentile
overall median 67 · Pharma: 43rd pctile, median 70 · Small: 60th pctile, median 66
Evidence depth
Financial-only
5 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
53
watch · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
26
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 3.1%.
- ▸Debt/equity is 0.07.
- ▸ROCE is 21.2%.
Trust risks
- ▸Only 1 years of positive FCF.
- ▸1/4 latest quarters had positive YoY revenue growth.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
- ▸OPM spread across recent quarters is 28.7%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Brooks Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 22 Aug - Addendum to the Notice of 24th Annual General Meeting.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 21 Aug - Brooks Laboratories issues AGM addendum; Resolution 4 amended for Rs.83.15 crore BSL transactions and Rs.48.15 crore guarantee.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.